Guido Eibl

5.4k citations
102 papers · 4.1k indexed · 1 hit paper · h-index 39

Guido Eibl

100 papers receiving 4.0k citations

Hit Papers

Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer3242017202620202023100200300

Peers

Guido Eibl
Comparison fields: 5 of 126
  • Oncology 2.0k
  • Cancer Research 839
  • Surgery 1.2k
  • Molecular Biology 1.8k
  • Pharmacology 369
Replace Goshi Shiota with:
Goshi Shiota Japan
Yanqiao Zhang China
Shigeki Nakagawa Japan
Junji Matsui Japan
Sang Cheul Oh South Korea
Takashi Kobayashi Japan
Aurelia Lugea United States
Ping Fan China
Michihisa Umetani United States
Zheng Wu China
Guido Eibl relative to Goshi Shiota Japan Goshi Shiota's profile →
Citations per field
00.5×
Goshi Shiota · 1×
Citations per year

Countries citing papers authored by Guido Eibl

Since Specialization
Citations

This map shows the geographic impact of Guido Eibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Eibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Eibl more than expected).

Fields of papers citing papers by Guido Eibl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Eibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Eibl. The network helps show where Guido Eibl may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Guido Eibl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guido Eibl Line = papers co-authored together Guido Eibl links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20244
2 20227
3 202210
4 20203
5 201918
6 201941
7 201844
8 201832
9 2017104
10 201424
11 201374
12 201020
13 2009258
14 200826
15 200586
16 200224
17 200115
18 200026
19 199954
20
[Value of magnetic resonance tomography in preoperative staging of stomach carcinoma].
19981

About Guido Eibl

Guido Eibl is a scholar working on Oncology, Cancer Research and Nephrology, having authored 102 papers that have together received 4.1k indexed citations. Recurring topics across this work include Pancreatitis Pathology and Treatment (28 papers), Pancreatic and Hepatic Oncology Research (28 papers), Inflammatory mediators and NSAID effects (16 papers), Metabolism, Diabetes, and Cancer (14 papers), Electrolyte and hormonal disorders (9 papers), Renal function and acid-base balance (8 papers), Cancer, Stress, Anesthesia, and Immune Response (8 papers) and Estrogen and related hormone effects (8 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (839 citations) and Surgery (1.2k citations). Guido Eibl has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include O. Joe Hines, Howard A. Reber, Enrique Rozengurt, James Sinnett‐Smith, Krisztina Kisfalvi, John P. Duffy, H. J. Buhr, Aune Moro, Hui-Hua Chang and Hubert G. Hotz. Their work appears in journals such as Pancreas, Cancer Research, Surgery, PLoS ONE and American Journal of Physiology-Gastrointestinal and Liver Physiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026